Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Period	TotalRevenue
2020-12-31	N/A
2021-12-31	$57.03M
2022-12-31	$25.82M
2023-12-31	$17.45M
2024-12-31	$182.95M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TARS	$61.45	+0.79%	0.72M
3
4
5

Tarsus Pharmaceuticals Inc. (TARS) Revenue History

Revenue Data

Get Tarsus Pharmaceuticals Inc. Data in Excel

More TARS Financial Data